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Abstract
A current key feature in drug-target network is that drugs often bind to multiple targets, known as polypharmacology or
drug promiscuity. Recent literature has indicated that relatively small fragments in both drugs and targets are crucial in
forming polypharmacology. We hypothesize that principles behind polypharmacology are embedded in paired fragments
in molecular graphs and amino acid sequences of drug-target interactions. We developed a fast, scalable algorithm for
mining significantly co-occurring subgraph-subsequence pairs from drug-target interactions. A noteworthy feature of our
approach is to capture significant paired patterns of subgraph-subsequence, while patterns of either drugs or targets only
have been considered in the literature so far. Significant substructure pairs allow the grouping of drug-target interactions
into clusters, covering approximately 75% of interactions containing approved drugs. These clusters were highly exclusive
to each other, being statistically significant and logically implying that each cluster corresponds to a distinguished type of
polypharmacology. These exclusive clusters cannot be easily obtained by using either drug or target information only but
are naturally found by highlighting significant substructure pairs in drug-target interactions. These results confirm the
effectiveness of our method for interpreting polypharmacology in drug-target network.
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Introduction
To understand the principles behind drug-target interactions is
important for safer and more efficacious treatment of diseases. A
recently-identified, key feature of drug-target networks is poly-
pharmacology or drug promiscuity, which is currently recognized
as important, because of a variety of reasons which can be
summarized into roughly four: 1) Exquisitely selective drugs for a
single target are likely to exhibit low clinical efficacy and be
unsuccessful [1]. 2) Multi-targeted drugs have been clinically
successful, particularly as dual or multiplex kinase inhibitors [2]. 3)
Many approved drugs, potentially the majority of therapeutic
agents, are less selective than initially thought [3]. An example is
cancer drugs such as Gleevec (imatinib) and Sutent (sunitinib) that
show binding promiscuity for multiple kinases [4]. 4) The
robustness of biological systems can be implied by the scale-free
nature of drug-target networks [5,6]. This means that some
mechanisms to compensate for dysfunction of a single protein
might exist, indicating that inhibiting a single target would be
therapeutically insufficient [1].
Recent analysis reveals that targets of promiscuous drugs can be
observed across different families abundantly [7] and can be
shared among drugs which are unrelated with each other, being in
different therapeutic categories [3]. These results suggest that
targets of promiscuous drugs can be dissimilar, implying that only
a small part of each target is related with the principle of
polypharmacology. Similarly, recent research shows that smaller
drugs in molecular weight are likely to be more promiscuous [6],
suggesting that small fragments in each ligand would be a key to
drug promiscuity. We hypothesize that paired fragments signifi-
cantly shared in drug-target pairs could be crucial factors behind
polypharmacology. Drugs (or chemical compounds) can be
typically represented by molecular graphs, and targets (or proteins)
are by amino acid sequences. Thus some key principles of
polypharmacology could be observed as paired fragments (or
substructures) of molecular graphs and amino acid sequences of
drug-target pairs. Currently many drug-target pairs are already
known, by which we can take a data-driven approach to search
substructure pairs significantly shared in the drug-target (graph-
sequence) pairs. We developed a scalable and efficient algorithm
for systematically exploring the substructure (subgraph-subse-
quence) pairs which significantly co-occur in currently available
drug-target pairs. We investigated the relation of the significant
substructure pairs to forming polypharmacology.
One experimental result we obtained in this analysis is
clustering drug-target pairs by significant substructure pairs.
Possible related work would be the analysis over a drug-target
network, e.g. [8]. However to the best of our knowledge, clustering
over a bipartite graph of drugs and networks has not been done
yet, implying that the first attempt of clustering drug-target pairs
with drug promiscuity is done by using substructure pairs in this
work.
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Results and data shown in this paper are all available at the
website, GRASP (GRAph-Sequence Pairs): http://www.bic.
kyoto-u.ac.jp/pathway/grasp.
Data
Our main data has two subsets: 1) 11,219 drug-target pairs
containing 4,191 compounds and 4,632 targets, derived from
DrugBank [9] of version 2.5 (January 29, 2009), and 2) Non-
interacting pairs, corresponding to all pairs between 4,191 com-
pounds and 4,632 targets except 11,219 drug-target pairs (Fig. 1 and
Methods section). The 4,191 compounds contain 1,082 approved
drugs (except those in the most minor two categories: ‘‘neutraceu-
tical’’ and ‘‘withdrawn’’), forming 2,723 drug-target pairs.
Capturing significantly co-occurring substructure pairs
We developed a fast data-mining algorithm that has two key
features:1) We exhaustively list up all frequently co-occurring pairs
of substructures in drag-target pairs. 2) For each of frequent
substructure pairs, we check the co-occurrence significance by a
statistical interaction test that evaluates the interdependence of two
substructures (Methods section, Methods S1 and Fig. 1). We
obtained 41,543,488 frequent substructure pairs co-occurring in at
least 5% in drug-target pairs and selected the 10,000 most
significantly co-occurring substructure pairs. The significant
substructure pairs had p-values (with no adjustment) of 10
221.71
to 10
2292.99 with the average of 10
234.73, being selected out of
approximately 4.15610
7 pairs and confirming the statistical
significance of the substructure pairs even under the Bonferroni
correction. The significant substructure pairs consist of 855 unique
drug substructures (subgraphs) with the averaged molecular weight
of 105.49 and the averaged size of 7.70 (hydrogen-suppressed)
atoms and 6.79 bonds, and 360 unique target substructures
(subsequences, being 174 with three-letter, 185 with two-letter and
1 with only one-letter) with the averaged length of 2.48 (Fig. 2a).
Given significant substructure pairs, for an arbitrary compound-
protein (graph-sequence) pair, we can compute a binary vector of
10,000 elements where if a significant substructure pair is
included, the value of the corresponding element is 1; otherwise
zero. We call this binary vector a GRASP fingerprint.
Profiling drug-target network through significant
substructure pairs
We generated a matrix of 11,219 drug-target pairs (rows) vs.
10,000 significant substructure pairs (columns) where an element
takes 1 if the corresponding drug-target pair has the corresponding
significant substructure pair; otherwise zero, making each row a
GRASP fingerprint (Fig. 3 and Fig. S1). The number of 1s in a row
ranges from zero to 7,272, the median being 226 (the first and
third quartiles being 22 and 978.5, showing an asymmetric
distribution) and the number of rows with no less than 226 1s
being 5,613. We performed hierarchical clustering on each
dimension of the matrix by using the Tanimoto coefficient (Tc)
between binary vectors and then selected the major part in
resultant clusters of each dimension for detailed analysis (Fig. 3
and Methods). On significant substructure pairs, we chose the 11
largest clusters (C1 to C11), covering 7,803 (78.03%) of all 10,000
and being further turned into seven groups (G1 to G7) by the
substructure similarity between clusters (Fig. 2a and Fig. 3). G1 to
G7 were characterized by drug substructures mainly: G1: sugar-
derived drug substructures, G2: carbon skeletons with a benzene
ring or nitrogen- or oxygen-containing carbon skeletons, G3:
carbon skeletons with a benzene ring, G4: oxygen-containing
carbon skeletons, G5: nitrogen-containing carbon skeletons, G6:
drug substructures (and target substructures) related with G
protein-coupled receptors (GPCRs), G7: sugar-phosphate-derived
drug substructures. On drug-target pairs, we chose the most major
Figure 1. The Proposed mining Algorithm. (a) The input was K drug-target pairs with m drugs and n targets, and (mxn–K ) non-interacting
pairs. Practically K=11,219, m=4,191, n=4,362, and mxn–K=18,269,923. (b) All frequently co-occurring substructure pairs in K drug-target pairs are
enumerated exhaustively, where a frequent substructure pair appeared in more than 560 drug-target pairs, i.e. 5% of 11,219 drug-target pairs. (c) The
significance of each frequent substructure pair is measured by an interaction test, i.e. log-likelihood test with logistic regression, which can provide p-
values for frequent substructure pairs to be ranked. (d) The output was N most significant substructure pairs, where in practice N=10,000.
doi:10.1371/journal.pone.0016999.g001
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11,219; Table S1) in which the number of rows, each having no
less than 226 1s, was 4,396, which was 96.0% of the 4,581 and
78.31% of the 5,613 rows with no less than 226 1s (Table S2 and
Fig. S2). Some of R1 to R8 were tightly and uniquely linked to
some of G1 to G7, such as R8 and G1 (Fig. 3). R1 to R8 covered
2,036 (74.77%) of the 2,723 approved-drug-containing drug-target
pairs. R1 to R8 were characterized by the most relevant GO terms
to targets (Fig. 2b and Table S3).
Clustered drug-target pairs by significant substructure
pairs reveal types of polypharmacology
Two drug-target pairs in a cluster should have a high
similarity in terms of GRASP fingerprints. In fact, the average
Figure 2. Major significant substructures and related GO terms. (a) Drug substructures and target substructures of significant substructure
pairs in each of 11 clusters (7 groups), removing redundancy by taking the maximum substructures when redundancy found in each cluster. (b) The
most relevant GO terms in molecular function and biological process are shown with p-values and the number of appearances for R1 to R8 and R3-G2
to R3-G6.
doi:10.1371/journal.pone.0016999.g002
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significantly higher than that in random clusters, each having
the same number of pairs randomly selected out of the 11,219
drug-target pairs (0.243 to 0.477 while that for random clusters
was 0.0374; empirical p-value,10
25; Methods and Table S4).
This feature was kept for drug-target pairs with promiscuous
drugs only (0.274 to 0.493 while that for random clusters was
0.0394; empirical p-value,10
25; Table S5). Drug-target pairs of
polypharmacology would be divided into different types, which
can be separated from each other. We hypothesize that each of
R1 to R8 corresponds to a unique type of polypharmacology.
To validate the hypothesis, given drugs and targets of drug-
target pairs in a cluster, we measured the ratio of interactions
fallen into the cluster to all interactions between them, which
was significantly higher than that by random clusters (0.935 to
1.0 while that for random clusters was 0.514 to 0.610; empirical
p-value,10
25; Table S6). For pairs with promiscuous drugs,
again this ratio was significantly high (0.915 to 1.0 while that for
random clusters was 0.498 to 0.619; empirical p-value,10
25;
Table S7). As such, the exclusiveness of R1 to R8 implies that
each of R1 to R8 might correspond to a unique polypharma-
cology type where each cluster was generated by the
corresponding set of significant substructure pairs. The highly
exclusive clusters cannot be found so clearly by using either drug
or target information only. This can be confirmed by that drug-
target pairs were clustered more clearly by GRASP fingerprints
than those by compound similarity only, sequence identity only
and using the sum of both (Fig. S3). In addition, the average
sequence identity between drug-target pairs sharing the same
drugs (i.e. promiscuous drugs) was only 0.0311, showing the
diversity of targets in promiscuous drugs and implying the
difficulty of clustering drug-target pairs by drug or target
i n f o r m a t i o no n l y( T a b l eS 8 ) .I n t e r a c t i o n si nR 1t oR 8c a nb e
shown as a drug-target network, where edges are colored
a c c o r d i n gt oR 1t oR 8( F i g .4 ) .T h i sf i g u r es h o w st h a te a c ho f
R1 to R8, in most cases, corresponds to a dense and relatively
non-overlapped subnetwork automatically. In particular, in
Fig. 4, R3 can be found as an upper-left subnetwork, while R8
forms a lower-right subnetwork. We emphasize that each of
these subnetworks can be explained by significant substructure
pairs uniquely. This indicates that our method of mining
significant substructure pairs provides with richer information
than the drug-target network itself and simple clusters which can
be obtained by running a graph clustering method over a drug-
target network.
Highly significant substructure pairs were specific to
GPCRs
Highly significant substructure pairs with the smallest p-values
were mainly in G6 (Fig. 2), which is closely related with GPCRs,
indicated by target substructures of G6, such as DRY, PFF, and
CW, known short sequences of GPCRs (G6 of Fig. 3a). In fact, DRY
is highly conserved in GPCRs, deeply involved with the GPCRs
activation by regulating the conformational states [10], and
Figure 3. A matrix of drug-target pairs vs. significant substructure pairs. Elements are colored differently according to seven groups (G1 to
G7) of significant substructure pairs. For each of drug-target pairs, the number of significant substructure pairs contained (NSSP), the 1
st level
Anatomical Therapeutic Chemical (ATC) classification classes for the drug and gene ontology (GO) terms for the target are shown on the right-hand
side of the matrix (Figure 2b for GO terms). For each of significant substructure pairs, the number of appearances in drug-target pairs (Support,
shown by the ratio to all pairs) and the p-value (–log10(p)) of interaction test are shown below the matrix.
doi:10.1371/journal.pone.0016999.g003
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accompanying with 8 subnetworks, each being one of R1 to R8. The size of nodes indicates the size of degrees (or promiscuity).
doi:10.1371/journal.pone.0016999.g004
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[11,12]. In addition, LPF, LVM, PFF, SID and CW form the main
part of the binding pocket in the 3D structure of a GPCR, i.e. b2-
adrenergic receptor bound to carazolol (Fig. 5), where ‘F’o fPFF
and ‘D’o fSID are important in ligand binding from mutagenesis
studies [13]. GPCRs have many conserved sequences, and it is
hard to specify known target substructures in G6, such as DRY,
PFF and CW, by using sequence information only, underlining the
importance of focusing on both drug and target substructures. On
drug substructures, endogenous ligands of adrenergic GPCRs such
as adrenaline, noradrenaline, dopamine, and serotonin having
propylamine (-C-C-C-N) and a benzene ring, were typical drug
substructures of G6.
Significant substructure pairs are less likely to appear in
random compound-protein pairs
Significant substructure pairs were small, and the GRASP-
fingerprint patterns in the current drug-target pairs might also be
found in non-interacting compound-protein pairs. To assess this
possibility quantitatively, we used compound-protein pairs with no
known interactions in DrugBank, and compound-protein pairs
from other sources: 1) POSI: 1,252 ligand-protein interactions
derived from PDB (Note that POSI does not have any of 11,219
interactions from DrugBank), 2) NEGA: 10,000 pairs randomly
chosen from non-interacting pairs, and 3) RAND: 10,000 pairs
randomly chosen from all combinations of 140,937 bioactive
compounds and 6,919 druggable proteins from PubChem and
Ensembl, respectively (Methods). For each pair in these datasets,
we computed Tc between the GRASP fingerprint of this pair and
the GRASP fingerprint of each of 11,219 drug-target pairs and
checked the highest Tc among the 11,219 pairs, to search for the
most similar drug-target pair in the 11,219 pairs (Methods S1).
The highest Tcs of POSI were mostly in between 0.95 and 1.0,
while those of NEGA and RAND were in a wider range (Fig. 6a
and Fig. S4). Under the same setting, compound similarity for
drugs and sequence identity for targets, instead of GRASP
fingerprints, showed broader distributions of similarities for the
three datasets which were overlapped with each other (Fig. 6b and
Fig. S4). From these results, significant substructure pairs were
more likely to appear in POSI than in NEGA and RAND. In
POSI, 63% of drug-target pairs which gave the highest Tc of
larger than 0.95 were not in any of R1 to R8 (Table S1), implying
a different property of ligand-enzyme pairs in PDB from those in
drug-target network.
Classifying all possible compound-protein pairs by
significant substructure pairs
The scalability of GRASP fingerprints on finding the most
similar drug-target pair to an arbitrary given compound-protein
(graph-sequence) pair was examined by generating 975,243,103
compound-protein pairs (which we call MASS) from 140,937
bioactive compounds and 6,919 druggable proteins (Methods
section and Methods S1). Practical computation time for detecting
the closest pair for each of all 975,243,103 pairs was totally less
than 100 hours, confirming the applicability of our method to a
real, large-scale drug-target analysis. Around 80% of drug-target
pairs which provided the highest Tcs of larger than 0.95 were in
R3, i.e. the most major cluster, implying that many unknown
drug-target pairs might be in MASS (Table S1).
Concluding remarks
Fragment-based drug design (FBDD), a widely-accepted
approach in drug discovery, breaks up drug leads into smaller
building blocks such as functional groups or scaffolds [14]. A basis
behind FBDD is ‘‘pharmacophore’’, by which common atom
conformations in binding sites are used for designing multi-
targeted drugs [6], and several pharmacophores over different
protein families are now known [15]. These facts agree with the
idea that only small portions are highly conserved structurally and
electronically, being vital to drug-target binding, which supports
our hypothesis. Our significant substructure pairs partitioned
drug-target pairs covering most of approved drugs into clusters,
which were clearly separated from each other, implying that each
cluster corresponds to a unique polypharmacology type. Current
analysis on drug-target networks has revealed that the true drug-
target network can be much denser than currently estimated [3],
but it would be hard for existing techniques, such as graph
clustering or approaches using either drug or target information
only, to systematically identify subnetworks, which must be denser
and further harder to do that with some explanation on protein
sequences and chemical structures. Our exclusive clusters suggest
that intra-cluster edges should be more likely generated than inter-
cluster edges, providing significant substructure pairs as a basis.
Methods
Data from DrugBank
DrugBank [9] is the most standard dataset that covers a wide
range of drug-target interactions. The ‘small molecules’ dataset of
Figure 5. 3D structure of GPCR and a ligand. (a) 3D structure of GPCR (b2 adrenergic receptor) and a ligand (Carazolol, colored black) derived
from PDB, target substructure in GPCR being colored according to the corresponding group of significant substructure pairs. (b) An enlargement of
(a), focusing on the binding site with target substructures including DRY (for activation), and CW, LPF, PFF, LVM and SID (for binding), all being in G6.
doi:10.1371/journal.pone.0016999.g005
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compounds where 4,730 had singly connected 2D structures and
4,191 of 4,730 had at least one known target. In more detail, 1,166
were approved, 3,014 were experimental, 284 were investigation-
al, 77 were illicit, 62 were nutraceutical, and 35 were withdrawn
compounds. The 4,191 compounds were linked to 4,362 targets,
resulting in 11,219 drug-target interactions we used, and non-
interacting pairs were all combinations from 4,191 compounds
and 4,362 targets except the 11,219 drug-target pairs (Fig. 1a).
Non-interacting pairs might contain unknown drug-target pairs,
which are we think statistically negligible, since non-interacting
pairs are huge. In 11,219 drug-target interactions, 1,447 (34.5%)
out of 4,191 drugs were promiscuous drugs, i.e. each with at least
two targets, and this percentage was consistent with 35% in Paolini
et al, 2006. These promiscuous drugs were involved with 8,475
interactions (75.5% of all 11,219 drug-target pairs) and 171,029
interaction pairs. 2D structures of drugs were converted into
hydrogen-suppressed molecular graphs where nodes were labeled
with atom types except for hydrogen atoms and edges are labeled
with bond types. All targets were treated as amino acid sequences.
Thus drug substructures and target substructures mean connected
subgraphs and consecutive subsequences, respectively.
The algorithm to generate significantly co-occurring
substructure pairs
We developed an efficient and scalable algorithm for mining the
N most significant substructure pairs from given drug-target pairs
(Fig. 1 and Methods S1). Our algorithm has two key features: 1)
Listing up all frequent substructure pairs (Fig. 1b): This is a
mathematical issue of enumerating all frequent pairs of subgraphs
and subsequences which appeared in more than a pre-specified
percentage (which is called support) in given graph-sequence pairs.
Our algorithm is most efficient and scalable for this problem
setting in terms of the current literature of frequent pattern mining
[16]. 2) Testing significance on frequent substructure pairs (Fig. 1c):
This test was performed because 1) frequent substructure pairs in
drug-target pairs may frequently appear in non-interacting pairs
and in this case they cannot be significant and 2) if any
substructure of a substructure pair is already frequently observed
in drug-target pairs rather than in non-interacting pairs, this
substructure pair might not be significant even if it appears more
frequently in drug-target pairs than non-interacting pairs. Thus we
used a statistical test which can measure the interdependence of
two substructures of a given substructure pair. This test is the same
as that for detecting ‘epistasis’ in genetics [17], and we used a
standard statistical test for this issue, i.e. likelihood ratio test with
logistic regression (The next paragraph for detail). In reality, the
two key features of our algorithm are merged into one procedure
in which each time a frequent substructure pair was found, its
statistical significance was tested, and if its p-value was lower than
that of the N-th pair in the N pairs kept in our procedure, we
stored the frequent substructure pair with its p-value and sorted the
currently stored all frequent substructure pairs again according to
their p-values; otherwise it was discarded. Practically, we obtained
41,543,488 frequent substructure pairs under the support of 5%,
Figure 6. Distributions of highest scores in similarity of POSI, NEGA, and RAND to 11,219 drug-target pairs. (a) Distributions of highest
Tcs of compound-protein pairs in POSI, NEGA and RAND over 11,219 drug-target pairs, in terms of GRASP fingerprints. (b) Distributions of highest
similarities of compound-protein pairs in POSI, NEGA and RAND over 11,219 drug-target pairs, where the similarity is given by compound similarity
plus sequence identity. Both (a) and (b) are the results obtained by only the cases that the number of substructure pairs shared between two GRASP
fingerprints is more than 100.
doi:10.1371/journal.pone.0016999.g006
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Core AMD Opteron Processor 2222SE (62) and 18G memory.
Real computation time of this algorithm was around 35 hours to
have the most significant 10,000 substructure pairs.
Likelihood ratio test with logistic regression
Given drug substructure G and target substructure S, a pair of
drug and target can have (1) both G and S, (2) G but not S, (3) S but
not G, or (4) neither G nor S. We can use regression analysis to
check the significance in the interaction between G and S. We let
X1 and X2 be dummy variables, corresponding to a drug and a
target, each of which takes 0 or 1 indicating that a drug (target) has
G (S). Let Y be the response variable, and we pose two logistic
regression models to explain Y (Y=1 for drug-target pairs and
Y=0for non-interacting pairs,): Letting g=b0+b1 X1+b2 X2, the
probability of Y=1is modeled as
P
(1)
X1X2~
exp(g)
1zexp(g)
and P
(2)
X1X2~
exp(gzb3X1X2)
1zexp(gzb3X1X2)
Given drug-target pairs and non-interacting pairs, these two
models are fitted by maximum likelihood estimation (for which we
used the Newton-Raphson method practically) independently.
Then, we have two maximum likelihoods ^ L L(1) for P
(1)
X1X2, and ^ L L(2)
for P
(2)
X1X2. To statistically evaluate whether or not b3=0, that is, to
evaluate whether or not there is an interaction effect between
given G and S, we compare ^ L L(1) and ^ L L(2) by likelihood ratio test.
The test statistic {2log(^ L L(1)=^ L L(2)) follows the chi-squared
distribution with one degree of freedom under the hypothesis that
b3=0. Thus, we can compute the p-value of the observed statistic,
which measures the strength of joint (synergistic) effect between
substructure G and substructure S in distinguishing drug-target
pairs from non-interacting pairs.
Clustering drug-target interactions through significant
substructure pairs
We generated a binary matrix of taking drug-target pairs on one
dimension and significant substructure pairs on the other, where if
a significant substructure pair is in a drug-target pair, the
corresponding element is 1; otherwise zero. On each dimension,
we performed hierarchical clustering with complete linkage by
using Tanimoto coefficient (Tc, which takes a value between zero
and one) as the similarity of each pair of binary vectors, resulting
in a dendrogram in which leave (external node) neighbors are
reordered so that the nearest neighbor should be closest in terms of
binary vectors. We used hierarchical clustering by the following
three reasons: 1) One necessary input of partitional clustering is
the number of clusters which is hard to decide while hierarchical
clustering does not need the number of clusters as its input. 2)
Hierarchical clustering can provide the detail of subclusters in the
resultant dendrogram. 2) Hierarchical clustering is well accepted
in the literature of biology and chemistry. On significant
substructure pairs, we placed a cut-off value at 0.92 against 1-
Tc in the dendrogram, resulting in 36 clusters. We then selected
11 largest clusters, which had more than 200 substructure pairs
per cluster. These 11 clusters were manually summarized into 7
groups (G1 to G7) based on cluster similarity. On drug-target
pairs, we placed a cut-off value of 0.95 against 1-Tc in the
dendrogram, resulting in 279 clusters. Out of 279 clusters, we
chose 13 largest clusters, which had more than 100 drug-target
pairs per cluster. We further checked the cluster density, i.e. the
average number of ones in all binary vectors in each cluster, and
selected the eight largest clusters (R1 to R8) in terms of the cluster
density. R1 to R8 covered 4,581 (40.83% of all 11,219; Table S1)
rows, 3,736 (44.1%) out of all 8,475 drug-target interactions of
promiscuous drugs and 47,552 out of all 171,029 interaction pairs
for promiscuous drugs. We assigned the most appropriate GO
term to each of R1 to R8 by casting all genes in each
corresponding cluster to GoStat [18], which performs Fisher’s
exact test by treating the casted genes as positives (case) and all
targets (proteins) in 11,219 drug-target pairs as negatives (control).
For R3 which are related with G2 to G6, we checked genes which
are in drug-target pairs that contain more than 80% of significant
substructure pairs in each of G2 to G6, and casted these genes to
GoStat to assign the most relevant GO term to each of R3-G2 to
R3-G6, respectively.
Random clusters for checking the properties of R1 to R8
A random cluster was generated by randomly selecting drug-
target pairs out of the original 11,219 drug-target pairs, keeping
the selected number the same as that of the corresponding cluster,
i.e. one of R1 to R8. Random clusters were generated 10
5 times,
and the results were averaged over the 10
5 runs.
2D-embedding of drug-target networks
We used Pajek [19] to draw the networks shown in Fig. 4. This
software implements the Fruchterman-Reingold layout algorithm
[20] for optimizing the network layout.
Similarity measures used between drug-target
interactions
Throughout the work, sequence identity between two targets (or
proteins) was the identity of Smith-Waterman alignment obtained
by using ssearch [21] (we put %identity=0 for E.10
210), and
compound similarity of two drugs (or compounds) was Tc between
two fingerprints, each with 881 bits, given in PubChem. The
compound similarity plus sequence identity was the sum of the
compound similarity and the sequence identity and dividing it by 2
to have the range of this value from zero to 1.
Datasets to confirm that significant substructure pairs
cannot be found in random compound-protein pairs
In PDBbind [22], 1,300 protein-ligand structures are carefully
selected from PDB as ‘refined set (version 2007)’, which is designed
to be a high-quality standard dataset for theoretical studies on
protein-ligand binding. However, in 1,274 cases of the 1,300
structures, the 3D structure of a protein is obtained for only a part
of the entire protein, meaning that only a part of the entire
sequences is kept in PDB (and PDBbind). We then manually
checked the Uniprot ID of each protein of 1,274 cases and
retrieved Uniprot sequences. We further removed 22 pairs, which
were in our dataset of drug-target pairs, and finally obtained 1,252
protein-ligand pairs, turning into POSI. Bioactive compounds
were 140,937 singly-connected components, being derived from
151,535 compounds that were marked as ‘active in any PubChem
BioAssay’ in PubChem as of January 29, 2009. Druggable proteins
were 6,919 proteins in Ensembl that had at least one of 191 Pfam
domains specified by [23], following the definition of druggable
genome [24]. RAND had 10,000 pairs randomly chosen from all
combinations of 140,937 bioactive compounds and 6,919
druggable proteins.
Scalability test
When we compute GRASP fingerprints of all 975,143,103
combinations of 140,937 bioactive compounds and 6,919
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equal size and assigned each block to a CPU. Practical
computation time to obtain 1,000,000 pairs with Tc of not less
than 0.9 was around 90–98 hours for a block.
Supporting Information
Figure S1 An enlargement of the matrix of Fig. 3, including all
major clusters of both significant substructure pairs and drug-
target pairs. From left to right on the three columns on the right-
hand side of the matrix, in the first column, an element is colored
red if the corresponding drug-target pair has an approved drug;
otherwise blue. In the middle column, an element is colored red if
the corresponding drug-target pair has GPCR; otherwise blue. In
the right column, an element colored red if the target of the
corresponding drug-target pair is a membrane protein; otherwise
blue.
(PDF)
Figure S2 Hierarchical clustering on drug-target pairs where R1
to R8 are specified with brief descriptions on representative drug-
target pairs or targets.
(PDF)
Figure S3 Symmetric heatmaps of similarities among 11,219
drug-target pairs in terms of (a) GRASP fingerprints, (b-1)
compound similarity plus sequence identity, (b-2) compound
similarity only and (b-3) sequence identity only, where a brighter
dot shows a higher similarity. In (a) the order of drug-target pairs
in rows follows that of Fig. 2 of the main text. In (b-1), the order of
drug-target pairs in rows is arranged so that the most similar pair
in terms of compound similarity plus sequence identity should be
as nearest as possible. In (b-2) and (b-3), the order of drug-target
pairs in rows follows that of (b-1).
(PDF)
Figure S4 (a) Distributions of highest Tc of compound-protein
pairs in POSI, NEGA and RAND, when the Tc was computed
between the GRASP fingerprints of two pairs. (b) Distributions of
highest similarities of compound-protein pairs in POSI, NEGA
and RAND, when the similarity is given by compound similarity
plus sequence identity.
(PDF)
Methods S1 Full details of the proposed algorithms.
(PDF)
Table S1 For each of R1 to R8, (a) the number of drug-target
pairs, (b) the number of drug-target pairs which gave the highest
Tc of larger than 0.95 for pairs in POSI and (c) the number of
drug-target pairs which gave the highest Tc of larger than 0.95 for
pairs in MASS.
(PDF)
Table S2 The number of drug-target pairs with the number of
drugs and targets in each of R1 to R8.
(PDF)
Table S3 The most related 30 GO terms with each of R1 to R8.
The most right column shows the value of the number of genes in
both the corresponding cluster and the corresponding GO term
divided by the number of genes in the corresponding GO term.
(PDF)
Table S4 For each of R1 to R8, the average Tc of paired
GRASP fingerprints over all drug-target pairs in the correspond-
ing cluster, and that over 105 clusters, each having interactions
randomly selected out of the original 11,219 drug-target pairs and
keeping the cluster size the same as that of the corresponding
cluster.
(PDF)
Table S5 For each of R1 to R8, the average Tc of paired
GRASP fingerprints over drug-target pairs of all promiscuous
drugs in the corresponding cluster, and that over 105 clusters, each
having interactions randomly selected out of the original 8,475
promiscuous drug-target pairs and keeping the cluster size the
same as that of the corresponding cluster.
(PDF)
Table S6 In each of R1 to R8, given drugs and targets of drug-
target pairs, the ratio of drug-target pairs which were in the
corresponding cluster to all drug-target pairs between them, and
the average over those of 105 clusters, each having drug-target
pairs randomly selected out of the original 11,219 drug-target
interactions and keeping the cluster size the same as that of the
corresponding cluster.
(PDF)
Table S7 In each of R1 to R8, given drugs and targets of drug-
target pairs (of promiscuous drugs), the ratio of drug-target pairs
which were in the corresponding cluster to all drug-target pairs
between them, and the average over those of 105 clusters, each
having drug-target pairs (of promiscuous drugs) randomly selected
out of the original 11,219 drug-target interactions and keeping the
cluster size the same as that of the corresponding cluster.
(PDF)
Table S8 The number of drug-target pairs sharing the same
drugs and the average sequence identity between target (amino
acid sequences) of these pairs.
(PDF)
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